Clinical Trial Update: A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing ASA404 plus docetaxel vs placebo plus docetaxel in second-line treatment of non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASA404 (vadimezan)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: TERMINATED